KR20190122664A - 헌팅턴 병 치료를 위한 PPARγ효현제 - Google Patents

헌팅턴 병 치료를 위한 PPARγ효현제 Download PDF

Info

Publication number
KR20190122664A
KR20190122664A KR1020197023202A KR20197023202A KR20190122664A KR 20190122664 A KR20190122664 A KR 20190122664A KR 1020197023202 A KR1020197023202 A KR 1020197023202A KR 20197023202 A KR20197023202 A KR 20197023202A KR 20190122664 A KR20190122664 A KR 20190122664A
Authority
KR
South Korea
Prior art keywords
subject
disease
huntington
therapeutically effective
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197023202A
Other languages
English (en)
Korean (ko)
Inventor
바바라 핀크
로렌스 스타인만
Original Assignee
코히러스 바이오사이언시스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 코히러스 바이오사이언시스, 인크. filed Critical 코히러스 바이오사이언시스, 인크.
Publication of KR20190122664A publication Critical patent/KR20190122664A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020197023202A 2017-01-18 2018-01-18 헌팅턴 병 치료를 위한 PPARγ효현제 Ceased KR20190122664A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762447741P 2017-01-18 2017-01-18
US62/447,741 2017-01-18
PCT/US2018/014240 WO2018136635A1 (en) 2017-01-18 2018-01-18 Pparϒ agonist for the treatment of huntington's disease

Publications (1)

Publication Number Publication Date
KR20190122664A true KR20190122664A (ko) 2019-10-30

Family

ID=62908392

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197023202A Ceased KR20190122664A (ko) 2017-01-18 2018-01-18 헌팅턴 병 치료를 위한 PPARγ효현제

Country Status (13)

Country Link
US (1) US20190350918A1 (enExample)
EP (1) EP3570841A4 (enExample)
JP (1) JP2020505448A (enExample)
KR (1) KR20190122664A (enExample)
CN (1) CN110461330A (enExample)
AU (1) AU2018210165A1 (enExample)
BR (1) BR112019014529A2 (enExample)
CA (1) CA3050104A1 (enExample)
EA (1) EA201991716A1 (enExample)
IL (1) IL268008A (enExample)
MX (1) MX2019008535A (enExample)
SG (1) SG11201906644YA (enExample)
WO (1) WO2018136635A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016229982B2 (en) 2015-03-09 2020-06-18 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
JP2020515639A (ja) 2017-04-03 2020-05-28 コヒラス・バイオサイエンシズ・インコーポレイテッド 進行性核上性麻痺の処置のためのＰＰＡＲγアゴニスト

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8895541B2 (en) * 2002-09-04 2014-11-25 James A. Carnazza Methods for inhibiting the development of huntington's disease
US20040224995A1 (en) * 2003-05-09 2004-11-11 University Of North Texas Health Science Center At Fort Worth Neuroprotective effects of PPARy agonists against cellular oxidative insults
US7223761B2 (en) * 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
DE10351744A1 (de) * 2003-10-31 2005-06-16 Schering Ag Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
JP2008515978A (ja) * 2004-10-13 2008-05-15 ユニバーシティ オブ コネチカット カンナビネルジック脂質リガンド
WO2009097996A1 (de) * 2008-02-07 2009-08-13 Sanofi-Aventis Verwendung von substituierten phenylimidazolidinen zur herstellung von arzneimitteln zur behandlung des metabolischen syndroms
WO2010040055A2 (en) * 2008-10-03 2010-04-08 Intekrin Therapeutics, Inc. Oral pharmaceutical formulations for antidiabetic compounds
EP2448412B1 (en) * 2009-07-01 2019-05-01 JDS Therapeutics, LLC Chromium complexes as enhancers of brain glucose transporters
AU2014364447A1 (en) * 2013-12-20 2016-08-04 Teva Pharmaceutical Industries Ltd. Use of laquinimod to delay Huntington's disease progression

Also Published As

Publication number Publication date
WO2018136635A1 (en) 2018-07-26
SG11201906644YA (en) 2019-08-27
AU2018210165A1 (en) 2019-08-01
JP2020505448A (ja) 2020-02-20
EP3570841A1 (en) 2019-11-27
CA3050104A1 (en) 2018-07-26
IL268008A (en) 2019-09-26
US20190350918A1 (en) 2019-11-21
BR112019014529A2 (pt) 2020-02-27
EA201991716A1 (ru) 2020-02-04
CN110461330A (zh) 2019-11-15
MX2019008535A (es) 2019-12-02
EP3570841A4 (en) 2020-08-19

Similar Documents

Publication Publication Date Title
CN116459244A (zh) 神经退行性疾病的治疗剂
US20200188358A1 (en) Methods for the treatment of depression
CN102143687B (zh) 4-氨基吡啶在改善具有脱髓鞘和其它神经系统状况的患者的神经-认知和/或神经-精神病学损伤中的用途
Egeberg et al. Clinical overview of dalfampridine: an agent with a novel mechanism of action to help with gait disturbances
EP3697399B1 (en) Therapeutic agents for use in the treatment of restless leg syndrome
KR20190122664A (ko) 헌팅턴 병 치료를 위한 PPARγ효현제
JP2002541198A (ja) 失禁の治療法
US6462089B1 (en) Method for correcting the vigilance disorders associated with myopathies
KR102693607B1 (ko) 하지 불안 증후군을 치료하기 위한 치료제
TWI494106B (zh) Ｎ－２－羥基－乙基－六氫吡－ｎ'－２－乙磺酸（ｈｅｐｅｓ）之止痛及反轉髓鞘脫失損傷用途
PFEFFERBAUM et al. Narcolepsy, paranoid psychosis, and tardive dyskinesia: a pharmacological dilemma
Freeman et al. ICU management of patients with Parkinson's disease or Parkinsonism
JP2001523724A (ja) 運動ニューロン病および脱髄病を治療するためのシチコリン
CN108025003B (zh) 前额叶皮质处理病症，步态和肢体障碍治疗
ES2203210T3 (es) Uso de un agonista de receptor nicotinico para la fabricacion de un medicamento para el tratamiento del trastorno obsesivo compulsivo.
WO2025163129A1 (en) Acetyl-leucine for treating parkinson´s disease
TW202539621A (zh) 用於治療巴金森氏症的治療劑
WO2024211310A1 (en) Methods of dosing spinogenic compounds
Cassidy rehabilitation of patients with traumatic brain injury
HK40036165A (en) Acetyl-leucine for use in treating restless leg syndrome
JPH0449235A (ja) 痴呆治療剤
BR112020007657B1 (pt) Uso de leucina, acetil-leucina ou um sal farmaceuticamente aceitável da mesma para tratamento da síndrome das pernas inquietas (rls)

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190807

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210115

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230308

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230509

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230308

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I